Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5950
    0.0000 (-0.00%)
     

  • NZD/EUR

    0.5551
    +0.0011 (+0.20%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    84.28
    +0.71 (+0.85%)
     

  • GOLD

    2,359.30
    +16.80 (+0.72%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,130.22
    +51.36 (+0.64%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,088.62
    +171.34 (+0.96%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.3430
    +0.8470 (+0.92%)
     

Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022

Inspire Medical Systems, Inc.
·1-min read
Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc.

MINNEAPOLIS, May 11, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace in New York, New York.

Inspire is scheduled to present at 1:15 p.m. Eastern Time. The presentation will be accessible via a live webcast at https://kvgo.com/ubs-global-healthcare-2022/inspire-medical-systems-may

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

ADVERTISEMENT

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989